毛细胞白血病:从毛细胞起源到BRAF新世界
本文综述了毛细胞白血病近60年的认识历程,从1958年最初描述为预后不良的白血病性网状内皮细胞增生症,到明确其B细胞起源及几乎普遍存在的BRAF V600E突变,并总结了从脾切除到靶向治疗(维莫非尼、Moxetumomab Pasudotox)的演变,以及英国临床与科学界的贡献。
要点
- 毛细胞白血病为罕见且诊断困难的B细胞白血病,多数患者预期寿命已接近一般人群。
- BRAF V600E突变几乎普遍存在于毛细胞白血病,是重要诊断与治疗靶点。
- 治疗从脾切除发展到靶向药物维莫非尼和Moxetumomab Pasudotox。
核心结论
- 毛细胞白血病从最初预后不良的描述发展为多数患者预期寿命接近一般人群的疾病。
研究设计与样本
- 本文为综述,覆盖过去6年毛细胞白血病研究亮点及英国临床与科学界的贡献。
主要发现
- 明确了毛细胞白血病的B细胞起源并发现BRAF V600E突变几乎普遍存在。
- 治疗从脾切除的初步成功发展到维莫非尼和Moxetumomab Pasudotox等靶向治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
For a disease initially described in 1958 as a leukaemic reticulo-endotheliosis associated with poor outcomes, we have come a long way in our understanding of Hairy cell leukaemia. The vast majority of patients diagnosed with this rare, often diagnostically challenging, leukaemia can now expect a lifespan that is similar to the general population. This article covers some of the highlights from the last 6 decades that have led to our current understanding of this fascinating leukaemia - from elucidation of its B-cell origin to discovery of the almost universal occurrence of the BRAF V600E mutation; from the initial successes reported with splenectomy to the more recent development of targeted therapies such as Vemurafenib and Moxetumomab Pasudotox. It also pays tribute to some of the outstanding research in this field focusing particularly on the significant contributions made by the clinical and scientific community in the UK.
引用
- Dearden C, Iyengar S. Hairy Cell Leukaemia: From Hairy Beginnings to a BRAF New World. Br J Haematol. 2020. PMID: 33190264. doi:10.1111/bjh.17158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。